Taltz® (ixekizumab) – New indication
June 1, 2020 - Eli Lilly announced the FDA approval of Taltz (ixekizumab), for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.
Download PDF
